Christmas Shutdown


We've only been at the helm for 6 months or so, but what a ride it's been so far. Many thanks to our avid readers who have continued to support us with your traffic, feedback, and comments across all of the different platforms.

It's been a tough year on the share market for many of us and we hope you've weathered the storm as well as possible, fingers crossed that 2019 is a little bit greener for us all.

We'll be taking a break over the festive season and will be back on deck early in the new year. Live content will continue to update, and we'll still be about if you have any questions, but please be aware that Upcoming IPOs and News is unlikely to be updated as we join you all in taking some well deserved time off!

Thanks again and see you next year.

2018 Scorecard updated, what else needs fixing?

We were advised that the 2018 Scorecard was being a bit finicky, not displaying some data and was being slow to load.

After taking a look and making some changes it’s looings better for us, but let us know if that’s not the case. Likewise, anything else you see that needs some fine tuning please let us know as we only run this site in our spare.

Thanks to those who emailed in to let us know.

Fiji Kava drops almost 40% at open.

fiji kava.PNG

In news that may not surprise many of you, Fiji Kava (FIJ) has posting very disappointing results as it joined the ASX At 11am this morning.

Currently sitting around 12.5 cents, down from 20 cents, investors saw almost 40% wiped off the share price as everyone looked to offload, making this 2018s worst performing IPO.

We opted to avoid this one and signs are not great for a big bounce back, but if you bought in and are opting to sit tight for now, we’d love to hear what you think.

Christmas comes early as Exopharm posts 100%+ gains.


Australian biopharmaceutical company Exopharm (ASX:EX1) is delivering bucket loads of Christmas joy today as trade opened at 1:30pm - take note Santa!

Limited access and strong backing ensured investors were in for treat as prices immediately gained over 100% on the IPOs ask, peaking at 43.5 cents before settling to 40 cents.

Exopharm is seeking to develop and then commercialise “exosomes” as therapeutic agents with the aim of increasing the human life span. That might sound the like stuff of science fiction, but today’s results are very real.

This will be one to watch in 2019 and congratulations to anyone who managed to get an allocation.

Yandal Resources edges ahead of ask at launch


Posting any gain is a good thing and Yandal Resources Limited (YRL) has managed to do just that as it joined the ASX at 1pm today.

Resources sector IPOs have been plentiful this year, with most failing to match their initial ask at open, but Yandal has managed to slip investors a 5% gain as trade kicked off at 21 cents.

Prices are likely to shift with greater intent as results from ongoing exploratory works makes it way to market, keep track of Yandal’s performance on our 2018 Scorecard.